SCHEMBL6859936

SCHEMBL6859936

CC(C)Cc1nc(-c2ccc(C(=O)O)cc2)n(Cc2ccc(-c3ccccc3)c(-c3nnn[nH]3)c2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 1/20 0.38
AGTR2 P50052 1/20 0.38
ALOX5AP P20292 2/20 0.35
PTGES O14684 1/20 0.35
ALOX5 P09917 1/20 0.35
LTC4S Q16873 1/20 0.35
NPC1 O15118 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PTGER4 P35408 2/20 0.34
MME P08473 1/20 0.34
HDAC6 Q9UBN7 1/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6006227 0.93 AGTR1 (0.42) AGTR1AGTR2NPC1CYP1A2CYP3A4
SCHEMBL6004300 0.84 AGTR1 (0.39) AGTR1AGTR2IDO1TDO2
SCHEMBL6007409 0.84 AGTR1 (0.40) AGTR1AGTR2NPC1CYP1A2CYP3A4
SCHEMBL6007319 0.83 AGTR1 (0.41) AGTR1AGTR2
SCHEMBL6006782 0.83 AGTR1 (0.44) AGTR1AGTR2HDAC6IDO1TDO2
SCHEMBL6008409 0.83 AGTR1 (0.39) AGTR1AGTR2ALOX5APALOX5NPC1
SCHEMBL6008415 0.83 AGTR1 (0.39) AGTR1AGTR2ALOX5APALOX5LTC4S
SCHEMBL6004139 0.82 AGTR1 (0.44) AGTR1AGTR2IDO1TDO2
SCHEMBL6004136 0.82 ALOX5AP (0.43) AGTR1AGTR2ALOX5APPTGESALOX5
SCHEMBL6005786 0.81 AGTR1 (0.45) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040121989-A1 such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure G.D. SEARLE & CO. 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121989-A1 such as methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure GLS, AGTR1, AGTR2 AGTR1 2/4885AGTR2 3/4885ALOX5AP 2026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.